GSK has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) in ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...

The Food and Drug Administration on Thursday delivered a split decision on a blood cancer drug from GSK, approving its use in ...

GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.

The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...

US regulators approved GSK Plc’s blood cancer drug, a decision that will allow the company to bring the medicine back to the ...

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...

The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) ...